How many times should PD-1 monoclonal antibody immunotherapy be administered?

PD-1 monoclonal antibody immunotherapy has been administered more than 3 to 5 times.

PD-1 monoclonal antibody immunotherapy is a novel class of anticancer drugs that can activate the immune system to attack tumors, and it is used in the treatment of various malignant cancers such as lung cancer, esophageal cancer, and colorectal cancer. The number of PD-1 monoclonal antibody treatments required depends on the patient's response to therapy and overall health condition. Generally, 3 to 5 treatments constitute one course. If no therapeutic effect is observed, use should be discontinued promptly. If significant improvement is seen, treatment may continue. PD-1 monoclonal antibody immunotherapy may cause certain side effects; mild cases may include loss of appetite, nausea, fatigue, and other gastrointestinal adverse reactions, while severe cases may involve immune-related inflammatory conditions such as pneumonia, colitis, and myocarditis. If patients cannot tolerate the treatment or experience severe side effects, therapy should be stopped.

The number of PD-1 monoclonal antibody treatments varies from person to person and cannot be generalized. Close monitoring of the patient's physical condition is essential during treatment, and any abnormalities should be reported to the physician immediately.